Business Context and Reporting Period
This Form 10-Q covers Becton, Dickinson and Company (BD) for the quarterly period ended March 31, 2003. BD operates through three principal segments: BD Medical Systems, BD Clinical Laboratory Solutions, and BD Biosciences. The company reported strong revenue growth driven by international markets and the transition to safety-engineered products, though this was partially offset by weaker demand in certain molecular biology reagents and competitive pressures.
Key Financial Metrics
| Metric | Q2 2003 | Q2 2002 | 6 Months 2003 | 6 Months 2002 |
|---|---|---|---|---|
| Revenues | $1,134,041 | $1,012,971 | $2,185,689 | $1,957,917 |
| Operating Income | $196,781 | $175,927 | $354,364 | $317,580 |
| Net Income | $142,040 | $129,188 | $255,678 | $228,861 |
| Diluted EPS | $0.54 | $0.48 | $0.97 | $0.85 |
| Gross Margin | 49.0% | 48.4% | 48.4% | 47.8% |
| Operating Margin | 17.4% | 17.4% | 16.2% | 16.2% |
| Cash from Operations (6mo) | $292,833 | |||
| Total Debt (Short + Long Term) | $1,291,511 (as of Mar 31, 2003) | |||
| Cash and Equivalents | $285,471 (as of Mar 31, 2003) |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 12% year-over-year for the quarter and six months. Organic growth (excluding foreign currency) was approximately 7% for the quarter and 8% for the six months. International revenue grew 19% (quarter) and 15% (six months), aided by the euro.
- Segment Performance:
- Medical: Revenues up 13% (9% organic), driven by safety-engineered products and prefillable drug delivery devices.
- Clinical Lab: Revenues up 12% (8% organic), supported by diagnostic systems and safety-engineered devices.
- Biosciences: Revenues up 6%, but operating income declined due to new product launch expenses and excess inventory reserves in molecular biology.
- Cost Structure: Selling and administrative expenses increased to 26.3% of revenue (from 24.4% prior year) due to IT system upgrades and new product launches. Gross margin improved to 49.0% due to a favorable product mix.
- Special Charges: The current period had no special charges, whereas the prior year quarter included $9.9 million in restructuring charges.
Guidance, Outlook, and Risks
- Capital Expenditures: Management expects fiscal 2003 capital spending to range between $275 million and $300 million.
- Restructuring Savings: Savings from the 2002 Medical segment restructuring are expected to be fully offset by remaining costs in 2003, with net savings of approximately $15 million anticipated beginning in fiscal 2004.
- Tax Rate: The effective tax rate is expected to remain at approximately 24% for the fiscal year.
- Subsequent Event: On April 9, 2003, BD issued $400 million in new long-term debt ($200 million at 4.55% due 2013 and $200 million at 4.9% due 2018).
- Risks and Contingencies:
- Legal Proceedings: Ongoing litigation includes 522 latex allergy claims (294 closed with no liability) and a patent infringement suit by Retractable Technologies, Inc. (trial reset to Feb 2004).
- Supply Chain: Potential shortages of components from West Pharmaceutical Services due to facility damage.
- Market Factors: Risks include healthcare cost containment, competitive pricing pressures, and the potential impact of the SARS epidemic.
Investor Verification Checklist
- Verify the sustainability of the 44% growth in prefillable drug delivery device sales.
- Monitor the resolution of the Retractable Technologies patent litigation and potential impact on safety-engineered product sales.
- Assess the timeline for realizing the projected $15 million annual savings from the 2002 restructuring program.
- Review the impact of the new $400 million debt issuance on future interest expense and liquidity ratios.
- Track the performance of the new blood glucose monitoring products and their effect on gross margins.